https://orcid.org/0009-0002-4700-1513
Recent Scholarly Works
An Engineered Prodrug Selectively Suppresses β-Lactam-Resistant Bacteria in a Mixed Microbial Setting.
Journal article ACS Infect Dis · July 11, 2025 The rise of β-lactam resistance necessitates new strategies to combat bacterial infections. We purposefully engineered the β-lactam prodrug AcephPT to exploit β-lactamase activity to selectively suppress resistant bacteria producing extended-spectrum-β-lac ... Full text Link to item CiteCobalt(III) Schiff Base Complexes as Irreversible Inhibitors of the Metallo-β-Lactamase NDM-1
Preprint · June 21, 2025 Antibiotic resistance is a critical global health concern. Roughly 2.8 million Americans are infected with antibiotic-resistant bacteria each year, leading to over 35,000 deaths. Of particular concern are Enterobacterales that express metallo-β-lac ... Full text CiteAn engineered prodrug selectively suppresses β-lactam resistant bacteria in a mixed microbial setting.
Journal article bioRxiv · August 3, 2024 The rise of β-lactam resistance necessitates new strategies to combat bacterial infections. We purposefully engineered the β-lactam prodrug AcephPT to exploit β-lactamase activity to selectively suppress resistant bacteria producing extended-spectrum-β-lac ... Full text Link to item CiteRecent Grants
Developing Prodrugs to Selectively Suppress Beta-lactam Resistant Bacteria
FellowshipPI-Fellow · Awarded by National Institutes of Health · 2026 - 2029Microbiome-Sparing ß-Lactam Prodrugs for Treating Resistant Urinary Tract Infections
ResearchGraduate Student · Awarded by North Carolina Biotechnology Center · 2026 - 2027View All Grants